CN1233189A - 用TNFR-Ig治疗哮喘 - Google Patents

用TNFR-Ig治疗哮喘 Download PDF

Info

Publication number
CN1233189A
CN1233189A CN97194455A CN97194455A CN1233189A CN 1233189 A CN1233189 A CN 1233189A CN 97194455 A CN97194455 A CN 97194455A CN 97194455 A CN97194455 A CN 97194455A CN 1233189 A CN1233189 A CN 1233189A
Authority
CN
China
Prior art keywords
tnfr
igg
asthma
protein
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97194455A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·伦茨提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1233189A publication Critical patent/CN1233189A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN97194455A 1996-05-08 1997-05-02 用TNFR-Ig治疗哮喘 Pending CN1233189A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08
US60/016,842 1996-05-08

Publications (1)

Publication Number Publication Date
CN1233189A true CN1233189A (zh) 1999-10-27

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194455A Pending CN1233189A (zh) 1996-05-08 1997-05-02 用TNFR-Ig治疗哮喘

Country Status (15)

Country Link
EP (1) EP0910413A2 (fr)
JP (1) JP2000510113A (fr)
KR (1) KR20000010825A (fr)
CN (1) CN1233189A (fr)
AR (1) AR007020A1 (fr)
AU (1) AU725408B2 (fr)
BR (1) BR9708928A (fr)
CA (1) CA2253557A1 (fr)
CO (1) CO4820397A1 (fr)
HR (1) HRP970224A2 (fr)
MA (1) MA24169A1 (fr)
PE (1) PE70698A1 (fr)
TR (1) TR199802238T2 (fr)
WO (1) WO1997041895A2 (fr)
ZA (1) ZA973843B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136988A0 (en) * 1997-12-29 2001-06-14 Regeneron Pharma Novel nucleic acid and polypeptide
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3488851A1 (fr) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Thérapies immunoablatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939121B2 (fr) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. Protéines liant le TNF
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (fr) * 1993-03-29 1994-09-30 David Banner Muteines du facteur de necrose tumoral
AU3111995A (en) * 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
CA2253557A1 (fr) 1997-11-13
MA24169A1 (fr) 1997-12-31
WO1997041895A2 (fr) 1997-11-13
ZA973843B (en) 1997-11-10
BR9708928A (pt) 2000-05-09
PE70698A1 (es) 1998-11-18
AU2776497A (en) 1997-11-26
KR20000010825A (ko) 2000-02-25
JP2000510113A (ja) 2000-08-08
AU725408B2 (en) 2000-10-12
EP0910413A2 (fr) 1999-04-28
WO1997041895A3 (fr) 1998-03-12
HRP970224A2 (en) 1998-04-30
AR007020A1 (es) 1999-10-13
CO4820397A1 (es) 1999-07-28
TR199802238T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
DE69636538T3 (de) Antagoniste von interleukin-15
CN1259973C (zh) 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
Renzetti et al. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
JP6325585B2 (ja) インターロイキン−２２のウイルス性肝炎の治療における応用
EP1941907B1 (fr) Inhibiteur de dysfonctionnement d'îlots transplantés dans un transplant d'îlots
JP4373495B2 (ja) Ｉｌ−１７受容体
CN1129224A (zh) 类胰高血糖素促胰岛素的多肽类似物组合物及其使用方法
CN1297357A (zh) 一种包含il－6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
JP2642942B2 (ja) 霊長動物造血成長因子の新規種族
CN1333785A (zh) 干扰素－β融合蛋白及用途
WO1996022308A9 (fr) Facteur de suppression d'appetit et procedes connexes
JP2004506448A (ja) ヒトＩＬ−１βに対する抗体
TW200803893A (en) Agents for suppressing the induction of cytotoxic T cells
CN1057099C (zh) 新的合成肽，其中间体及其生产方法
CN1233189A (zh) 用TNFR-Ig治疗哮喘
WO2021068971A1 (fr) Formulation d'anticorps anti-cd20 et utilisation d'anticorps anti-cd20 pour le traitement de maladies positives pour le cd20
Xiu et al. Bronchial hyperresponsiveness and airway neutrophil accumulation induced by interleukin‐8 and the effect of the thromboxane A2 antagonist S‐1452 in guinea‐pigs
CA2382425A1 (fr) Mutants d'interferon tau et leurs techniques de preparation
US5958442A (en) Oncostatin M for treating inflammation
JPH11500904A (ja) Ｍｐｌリガンド類似体
EP0456842B1 (fr) Application medicinale de m-csf
CN1229138C (zh) 加速粘液纤毛的清除速率的方法
HK1022424A (en) Treatment of asthma with tnfr-ig
US9217018B2 (en) HSP70 fusion protein conjugates and uses thereof
JP2007530419A (ja) 改良組換えヒトインターフェロン−β−１ｂポリペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1056076

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1022424

Country of ref document: HK